Ahmed Koriesh/LinkedIn
Mar 27, 2026, 17:19
Ahmed Koriesh: Would You Start DAPT If the Patient Presents After 24 Hours?
Ahmed Koriesh, Director of Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”Would you start DAPT if the patient presents after 24 hours?
Yes — why not.
The key concept
- Stroke recurrence risk is front-loaded.
- Highest risk in the first 3–7 days
- Then declines significantly
When you look at recurrence curves:
Steep early rise to gradual flattening
Why this matters
- Early phase equals unstable plaque, high embolic risk
- This is where DAPT has the greatest impact
Practical take
- <24h: ideal (trial-based)
- 24h – several days: still meaningful benefit
- Approxmately 1 week: diminishing returns
There is no sharp cutoff — it’s a gradient, not a binary window
What about the Trials?
- Trials (CHANCE/POINT) used ≤24h to maximize efficacy
- But biology doesn’t stop at 24h
- Risk – and potential benefit – persists beyond that
Bottom line
If patient present with minor stroke after 24h, still within few days, would still benefit from DAPT to reduce recurrence, specially in high risk patients.”

Stay updated with Hemostasis Today.
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region
-
Jun 26, 2026, 10:11Kayla Kilani: First-Ever CT Perfusion Scan Performed Inside a Mobile Stroke Unit
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST
-
Jun 26, 2026, 07:10Saleh Shamse Basha: Why APTT Alone Can Be Misleading During UFH Monitoring
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk